EOLS - Evolus shares rise on upbeat 2024 revenue outlook
2024-01-16 17:58:56 ET
More on Evolus
- Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth
- Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript
- Public Citizen petitions FDA for stricter warnings against Botox, similar drugs
- Evolus GAAP EPS of -$0.30 misses by $0.01, revenue of $50M beats by $5.62M
- Seeking Alpha’s Quant Rating on Evolus
For further details see:
Evolus shares rise on upbeat 2024 revenue outlook